



PRODUCT SPECIFICATION

| | | | | | | | | | | | | | |
|----------------------|---|------------|--------|----------|--------|-----------|--------|-------|--------|-------|--------|------------|--------|
| catalog number: | J66100 | | | | | | | | | | | | |
| product description: | CA 19-9 Gastrointestinal Cancer Antigen | | | | | | | | | | | | |
| lot number: | [lot specific] | | | | | | | | | | | | |
| source: | Human fluids | | | | | | | | | | | | |
| form: | Liquid, aseptically filtered | | | | | | | | | | | | |
| purity: | [lot specific] KU/mL per OD _{280nm} (activity/mL @ OD _{280nm}) | | | | | | | | | | | | |
| buffer: | 50mM PBS, pH 7.4 ±0.2 | | | | | | | | | | | | |
| preservative: | 0.09% (w/v) NaN ₃ | | | | | | | | | | | | |
| concentration: | [lot specific] KU/mL (by Roche-cobas e 411) | | | | | | | | | | | | |
| bioburden: | <10 CFU/mL | | | | | | | | | | | | |
| cross-reactivity: | <table><tr><td>▪ CA 15-3</td><td>< 1.0%</td><td>▪ CA 125</td><td>< 1.0%</td></tr><tr><td>▪ CA 72-4</td><td>< 1.0%</td><td>▪ CEA</td><td>< 1.0%</td></tr><tr><td>▪ AFP</td><td>< 1.0%</td><td>▪ Ferritin</td><td>< 1.0%</td></tr></table> | ▪ CA 15-3 | < 1.0% | ▪ CA 125 | < 1.0% | ▪ CA 72-4 | < 1.0% | ▪ CEA | < 1.0% | ▪ AFP | < 1.0% | ▪ Ferritin | < 1.0% |
| ▪ CA 15-3 | < 1.0% | ▪ CA 125 | < 1.0% | | | | | | | | | | |
| ▪ CA 72-4 | < 1.0% | ▪ CEA | < 1.0% | | | | | | | | | | |
| ▪ AFP | < 1.0% | ▪ Ferritin | < 1.0% | | | | | | | | | | |
| manufacture date: | [lot specific] | | | | | | | | | | | | |
| expiration date: | [lot specific] | | | | | | | | | | | | |
| storage: | 2-8°C | | | | | | | | | | | | |
| hazard/biohazard: | <p>This material contains sodium azide as a preservative; take appropriate precaution.</p> <p>Donor material has been tested and found negative for HBsAg, anti-HCV and anti-HIV 1&2 by FDA approved methods. Donors tested negative for viral DNA/RNA for HBV, HIV 1 and HCV by PCR. However, this material should still be handled with caution as potentially hazardous.</p> | | | | | | | | | | | | |